BrainStorm Cell Therapeutics, Inc. (BCLI.OB) Receives Funding for ALS Research
Today, leading developer of adult stem cell technologies BrainStorm Cell Therapeutics Inc. announced that it has secured the necessary funding to complete pre-clinical trials for treatments of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The funding includes a prestigious grant from the Israeli government’s Office of the Chief Scientist (OCS) as well as a private investment. CEO of BrainStorm, Rami Efrati, stated, “We are very gratified to receive these financial votes of confidence in our breakthrough stem cell technology. The new funding will enable us to complete our pre-clinical studies in ALS and meet our goal of…